AmBisome is a brand name for liposomal amphotericin B, a potent antifungal medication used primarily in the treatment of severe fungal infections and certain protozoal diseases. It is specifically designed to target fungal cells without causing significant harm to human cells, making it a preferred choice for treating life-threatening conditions such as systemic fungal infections and leishmaniasis. The liposomal formulation of amphotericin B allows for a reduction in some of the drug's side effects, including kidney damage, which is a common concern with the non-liposomal form. AmBisome is administered intravenously, and its use is generally reserved for hospital settings or under the close supervision of healthcare professionals due to the seriousness of the infections it treats and the potential for adverse reactions.